ATXI - Vasta Platform Ensysce Biosciences X4 Pharmaceuticals among premarket losers' pack
Avenue Therapeutics (NASDAQ:ATXI) -22% after pricing $2M stock offering. X4 Pharmaceuticals (NASDAQ:XFOR) -11% presents new clinical and scientific data at 2021 ASH annual meeting supporting broader potential for Mavorixafor in the treatment of primary Immunodeficiencies. Vasta Platform (NASDAQ:VSTA) -13%. Context Therapeutics (NASDAQ:CNTX) -12%. Ensysce Biosciences (NASDAQ:ENSC) -6%. Inspira Technologies (NASDAQ:IINN) -5%. Auddia (NASDAQ:AUUD) -6% on Q3 earnings release. Energy Focus (NASDAQ:EFOI) -5% on Q3 earnings release.
For further details see:
Vasta Platform, Ensysce Biosciences, X4 Pharmaceuticals among premarket losers' pack